Disclosed are very high optically pure D- and L-lactic acid fermentation production strains and construction methods thereof and the method for preparing very high optically pure D- and L-lactic acids using the strains, wherein the deposit number of the D-lactic acid fermentation production strain is CGMCC No. 11059, and the deposit number of the L-lactic acid fermentation production strain is CGMCC No. 11060.

The present invention relates to an isolated strain of lactic acid bacteria (LAB) for inhibiting drug-resistant Enterobacteriaceae, in which the isolated strain of the LAB includes Lactobacillus rhamnosus JJ101, Lactobacillus paracasei JJ102 and/or Lactobacillus plantarum JJ103, and the isolated strain of the LAB inhibit growth of the drug-resistant Enterobacteriaceae. After orally administered to a subject, the isolated strain of the LAB can inhibit the growth of the drug-resistant Enterobacteriaceae, and thus can potentially be used to prevent, improve and/or treat the infection of the drug-resistant Enterobacteriaceae.

A method for screening Lactobacillus casei fermentation agent is provided. The method is specifically implemented by screening a Lactobacillus casei strain with high-expression of a lac cluster gene and no enzymatic activity of -fructosidase. The Lactobacillus casei strain that rapidly metabolizes lactose is screened through high expression of the lac cluster gene, such that the problem of large differences in acid production in fermented milk beverage products is avoided.

The present invention refers to a composition containing a) a fermented supernatant, or fractions thereof, of Lactobacillus casei or paracasei species, the species being characterized by having in their DNA genome at least one DNA sequence essentially identical to one of the sequence selected from the group consisting of: SEQ ID No 1 to 5, and b) proper carriers and/or diluents and/or excipients. The fermented supernatant is obtainable through a method characterized by the fermentation of the Lactobacillus casei or paracasei species in a minimum solution additioned with prebiotic fibers. The fermented supernatant does not have prebiotic fibers.

An agent for the prevention and treatment of chlamydia infection containing Lactobacillus casei as an active ingredient which is an agent for the prevention and treatment of chlamydia infection that is highly safe and that can be administered over an extended period of time.

The invention relates to a bacterial strain, Lactobacillus casei IPLA12038 with deposit number CECT 8590, and its use for the degradation of gluten, gliadin or derivative peptides. The strain has been isolated from an acidic dough used to make bread. Its advantages include the ability to use gliadin as nitrogen source, possess peptidase activities involved in the degradation of it and be able to completely degrade the immunotoxic (33) amino acid peptide involved in triggering of celiac disease in a short period of time. The fact of considering it a GRAS and QPS microorganism, isolated from a fermented food, sensitive to antimicrobial gastrointestinal agents and resistant to gastrointestinal conditions tested in vitro, guarantees its use as a probiotic or nutraceutical supplement.

The present invention discloses strains of Lactobacillus and Streptococcus which have a capacity to degrade gliadin peptides involved in coeliac disease and which peptide degrading activity is stable under low pH and in the presence of mammalian digestive enzymes. These strains are suitable in a product for use in prevention and/or treatment of celiac disease.

This invention relates to use of a strain of probiotic bacteria or derivatives thereof for increasing feed efficiency, enhancing growth and/or productivity, improving body weight or body composition, and/or increasing milk production in a ruminant animal, inhibiting the growth of methane-producing bacteria and/or archaea in the forestomach of ruminant animals, reducing the ability of the rumen microbiome to produce methane, reducing methane emissions by a ruminant animal, and/or reducing the greenhouse gas emission footprint of a ruminant animal. Ruminant feed compositions are also provided.

The present disclosure discloses multifunctional lactobacilli capable of relieving a toxic effect of perfluorooctanoic acid (PFOA) and use thereof, and belongs to the technical field of microorganisms. Lactobacillus fermentum CCFM1051, Lactobacillus casei CCFM1052 and Lactobacillus buchneri CCFM1053 of the present disclosure have high adsorption effect on PFOA, can significantly relieve liver oxidative stress damage and serum biochemical indicators caused by PFOA, spleen atrophy caused by PFOA exposure, imbalance of intestinal microorganisms caused by PFOA exposure and metabolic disorder of intestinal flora caused by PFOA exposure, significantly increase the content of acetic acid and propionic acid in the intestinal tract, increase the fecal water content and decrease first black stool defecation time of mice with constipation, improve proliferation and MafA gene expression of INS-1 cells under high glucose, have the potential to relieve PFOA-related diabetes, reduce occurrence of liver diseases, metabolic diseases and potential carcinogenicity, and have broad use prospects.

Fermentation process intended to produce metabolites modulating the epigenetic imprint characterized in that the fermentation is carried out with biosourced ingredients at a temperature between 45 and 50 C. for 180 hours by a co-culture of at least three bacterial strains that have been evolved by exposure to space environment conditions.